Impact of Prosthesis-Patient Mismatch on Hemodynamics During Exercise in Patients With Aortic Stenosis After Transcatheter Aortic Valve Implantation With a Balloon-Expandable Valve

Haruka Kameshima 1, Masaki Izumo 1, Tomomi Suzuki 1, Hiroshi Ohara 2, Yukio Sato 1, Mika Watanabe 1, Shingo Kuwata 1, Kazuaki Okuyama 1, Ryo Kamijima 1, Manabu Takai 1, Seisyou Kou 1, Yasuhiro Tanabe 1, Tomoo Harada 1 and Yoshihiro J. Akashi 1*

1 Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 2 Division of Cardiovascular Medicine, Department of Internal Medicine, Toho University Faculty of Medicine, Tokyo, Japan

Background: There is no evidence of hemodynamic performance during exercise in patients with aortic stenosis (AS) after transcatheter aortic valve implantation (TAVI). This study aimed to investigate the changes in kinematic hemodynamics during exercise and determine the impact of prosthesis-patient mismatch (PPM) on the hemodynamics of transcatheter heart valves using exercise stress echocardiography (ESE) in AS patients after TAVI.

Methods and Results: This study enrolled 77 consecutive patients (mean age 82 ± 5 years, 50.6% male) who underwent ESE 3–6 months after TAVI with a balloon-expandable valve. The effective orifice area index at rest was significantly correlated with the mean pressure gradient (PG) during exercise (p < 0.001). The patients were divided into two groups according to the presence of PPM (PPM and non-PPM groups). During exercise, the patients with PPM had a higher left ventricular ejection fraction (74.6 ± 6.1% vs. 69.7 ± 9.6%, p = 0.048), a lower stroke volume index (47.2 ± 14.0 ml/m² vs. 55.6 ± 14.5 ml/m², p = 0.037), a significantly higher mean transvalvular PG (21.9 ± 9.1 mmHg vs. 12.2 ± 4.9 mmHg, p = 0.01) and an increased mean PG from rest to exercise (5.7 ± 3.5 mmHg vs. 2.3 ± 2.8 mmHg, p < 0.001) compared with patients without PPM. Patients with PPM had a higher pulmonary artery systolic pressure (SPAP) during exercise (57.3 ± 13.8 mmHg vs. 49.7 ± 10.9 mmHg, p = 0.021) and a higher incidence of exercise-induced pulmonary hypertension (43.8 vs. 15.0%, p = 0.037) than patients without PPM. PPM was strongly associated with exercise-induced pulmonary hypertension (hazard ratio: 3.570, p = 0.013).

Conclusions: AS patients with PPM after TAVI showed a disproportionate increase in the transvalvular PG and SPAP during exercise, and PPM was associated with exercise-induced pulmonary hypertension.

Keywords: prosthesis-patient mismatch (PPM), aortic stenosis (AS), transcatheter aortic valve implantation (TAVI), exercise induced pulmonary hypertension, exercise stress echocardiography
INTRODUCTION

Aortic stenosis (AS) has become a common public health problem in the aging society. Transcatheter aortic valve implantation (TAVI) has changed the paradigm of care for AS patients and is currently being assessed for use in patients with a low surgical risk (1). As the indications for TAVI expand, the age of patients eligible for this type of treatment is decreasing and their level of activity in daily life is increasing accordingly. As a result, transcatheter heart valves (THVs) should have longer durability and better hemodynamic performance.

Prosthesis-patient mismatch (PPM) was first defined in 1978 to describe the mismatch between the hemodynamics of a valve prosthesis and the patient requirements for cardiac output (CO) (2). PPM occurs when the effective orifice area (EOA) of the prosthetic valve is very small in relation to the body surface area (BSA) of the patient, thus resulting in high residual postoperative pressure gradients (PGs) across the prosthesis. This problem is associated with postoperative prognosis (3–6) and prosthetic valve durability (7), and more recently, severe PPM has also been reported to be associated with prognosis after TAVI (6, 8, 9). However, to the best of our knowledge, there is no evidence of changes in hemodynamic performance during exercise in AS patients after TAVI. Therefore, the purpose of this study was to investigate the kinematic hemodynamics during exercise and determine the impact of PPM on the hemodynamics of THVs using exercise stress echocardiography (ESE) in AS patients after TAVI.

MATERIALS AND METHODS

Study Population and Study Design

This study retrospectively reviewed 256 consecutive patients who underwent TAVI with a balloon-expandable valve between January 2016 and December 2018 at the St. Marianna University School of Medicine Hospital. The Balloon-expandable valve devices were Sapien XT and Sapien 3 (Edwards Lifesciences, Irvine, CA, USA). Among these, 77 patients who underwent ESE 3–6 months after TAVI were enrolled in our study. Figure 1 is a flow diagram of this study. All TAVI procedures were performed under general anesthesia. The study was performed in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of the St. Marianna University School of Medicine, Japan (No. 1288). Written informed consent was obtained from all the patients.

Exercise Stress Protocol

Exercise was performed using the symptom-limited bicycle exercise test in the semi-supine position on a dedicated tilting exercise table at an initial workload of 10 Watt for 3 min, followed by a 10 Watt increase in workload every 3 min. Two-dimensional imaging and Doppler echocardiography data were obtained throughout the exercise test. The endpoints for terminating exercise were as follows: target heart rate reached, symptoms developed; blood pressure of <80 or >220 mmHg; ischemic electrocardiogram changes; ventricular arrhythmia; and rapid atrial tachycardia.

Transthoracic Echocardiography

Transthoracic echocardiography (Vivid E9; GE Vingmed Milwaukee, WI, USA) was performed at rest and during exercise. All images were digitally stored for offline analysis (EchoPAC, version 12; GE Vingmed Milwaukee, WI, USA), and they included standard two-dimensional, color, pulsed, and continuous-wave Doppler acquisitions according to the current American Society of Echocardiography guidelines (10). Left ventricular (LV) end-diastolic and end-systolic volumes and LV ejection fraction (LVEF) were measured from the standard apical views, according to Simpson's disk summation method. Stroke volume (SV) was measured in the left ventricular outflow tract (LVOT) using the Doppler method, and it was related to the BSA. The CO was obtained by multiplying the SV with heart rate. LV mass was calculated using two-dimensional images and the area-length method (10). To assess LV diastolic function, transmirtal early (E-wave) and late (A-wave) velocities were measured using pulsed-wave Doppler imaging at the mitral leaflet tips. The peak early diastolic velocities of the septal mitral annulus (e') were measured using pulsed-wave tissue Doppler imaging from the apical 4-chamber view, and the E/e' ratio was calculated. Suspected pulmonary artery pressure (SPAP) was estimated based on the Doppler spectral signal of the tricuspid regurgitation jet. Pulmonary hypertension (PH) was defined as an SPAP of ≥40 mmHg at rest, and exercise-induced PH was defined as an SPAP of ≥60 mmHg during exercise. PPM was defined as an EOA index (EOAi) of ≤0.85 cm²/m². The EOA of the THVs was calculated using the continuity equation, according to the current consensus document (11). From a zoomed parasternal long-axis view, the LVOT diameter was measured just below the apical border, i.e., from the outer border to the outer border of the stent or ring. To measure the LVOT flow velocity, the pulsed-wave Doppler was placed immediately below the apical border of the stent, with no valve opening or closing clicks visible. The transprosthetic flow velocity was determined by continuous-wave Doppler imaging with multiwindow interrogation, including the apical and right atrial outflow tracts.

FIGURE 1 | Flow diagram of patient recruitment. TAVI, transcatheter aortic valve implantation; ESE, exercise stress echocardiography; PPM, prosthesis-patient mismatch.
parasternal windows. The valvulo-arterial impedance (Zva) was calculated using the following formula (12):  
\[ Zva \text{ (mmHg/ml/m}^2\text{)} = \frac{\text{mean transvalvular PG} \text{ (mean PG)} + \text{systolic blood pressure}}{\text{SV/BSA}} \. \]  
Paravalvular leak was evaluated according to the Valve Academic Research Consortium 3 (13). The patients were divided into two groups according to the presence of PPM (PPM and non-PPM groups).

Computed Tomography
Preprocedural multidetector computed tomography was performed, and aortic annulus area was measured from 3-dimensional reconstruction recommended by the Society of Cardiovascular Computed Tomography guidelines (14).

Clinical Outcomes
The primary endpoint of this study was composite outcomes, including all-cause mortality, cardiovascular mortality, cardiovascular event, and heart failure-related hospitalization. The events were determined by reviewing the patients’ medical reports or via direct telephonic contact with the patients’ families.

Statistical Analysis
All analyses were performed using SPSS (version 26.0.0, IBM Corporation, Somers, New York). Continuous variables are presented as mean ± standard deviation and were tested for differences using the Student’s t-test. Categorical variables are presented as frequencies and percentages. The chi-squared and Fisher’s exact tests were used to compare the PPM and non-PPM groups. The relationship between the preoperative and postoperative mean PG and the EOAi was evaluated using a simple inverse regression analysis, with r-values (Pearson’s correlation coefficient). Survival was estimated using Kaplan-Meier analysis and compared using the two-sided log-rank test. The effects of clinical and echocardiographic parameters were assessed using the Cox proportional hazard model. Statistical significance was set at \( p < 0.05 \).

RESULTS
Clinical and Pre-procedural Echocardiographic Characteristics
Patients with PPM accounted for 17 (22.1%) of the total 77 patients, which included 15 (19.5%) patients with moderate

### TABLE 1 | Procedural results and baseline characteristics.

|                     | All (\( n = 77 \)) | PPM (\( n = 17 \)) | Non-PPM (\( n = 60 \)) | \( p \)-value (PPM vs. non-PPM) |
|---------------------|--------------------|--------------------|------------------------|-------------------------------|
| Age, years         | 82 ± 5             | 80 ± 6             | 83 ± 4                 | 0.003                         |
| Men, n (%)         | 39 (50.6)          | 7 (41.2)           | 32 (53.3)              | 0.742                         |
| Body surface area, m² | 1.50 ± 0.17       | 1.50 ± 0.13       | 1.50 ± 0.18            | 0.855                         |
| Hypertension, n (%) | 65 (84.4)         | 12 (15.6)          | 53 (88.3)              | 0.086                         |
| Diabetes, n (%)    | 16 (20.8)          | 3 (17.6)           | 13 (21.7)              | 0.507                         |
| Hypercholesterolemia, n (%) | 51 (66.2) | 11 (15.6) | 40 (66.7) | 0.548                         |
| Chronic kidney disease, n (%) | 51 (66.2) | 10 (58.8) | 41 (68.3) | 0.325                         |
| Atrial fibrillation, n (%) | 31 (40.3) | 6 (35.3) | 25 (41.7) | 0.428                         |
| Coronary artery disease, n (%) | 27 (35.1) | 3 (17.6) | 24 (40.0) | 0.075                         |
| Myocardial infarction, n (%) | 6 (7.8) | 2 (11.8) | 4 (6.7) | 0.397                         |
| Pre procedure NYHA class |              |                    |                        |                               |
| I, n (%)           | 47 (61.0)          | 12 (70.6)          | 35 (58.3)              | 0.554                         |
| II-IV, n (%)       | 28 (36.4)          | 5 (29.4)           | 23 (38.3)              |                               |
| Post procedure NYHA class |              |                    |                        | 0.467                         |
| I, n (%)           | 64 (83.1)          | 13 (76.5)          | 51 (85.0)              |                               |
| II, n (%)          | 13 (16.9)          | 4 (23.5)           | 9 (15.0)               |                               |
| III-IV, n (%)      | 0 (0)              | 0 (0)              | 0 (0)                  |                               |
| STS score          | 5.01 ± 2.64        | 4.45 ± 2.21        | 5.17 ± 2.74            | 0.324                         |
| Annulus area, mm²  | 425 ± 89           | 365 ± 64           | 442 ± 89               | 0.001                         |
| THV size           |                    |                    |                        | 0.001                         |
| 20 mm, n (%)       | 5 (8.5)            | 3 (17.6)           | 2 (3.3)                |                               |
| 23 mm, n (%)       | 36 (46.8)          | 13 (76.5)          | 23 (38.3)              |                               |
| 26 mm, n (%)       | 31 (40.3)          | 1 (5.9)            | 30 (50.0)              |                               |
| 29 mm, n (%)       | 5 (6.5)            | 0 (0)              | 5 (8.3)                |                               |
| Approach           |                    |                    |                        | 0.276                         |
| Trans-femoral, n (%) | 72 (93.5)       | 17 (100)           | 55 (91.7)              |                               |

Data presented as mean ± standard deviation or n (%). PPM, prosthesis-patient mismatch; CABG, coronary artery bypass grafting; NYHA, New York Heart Association; STS, The Society of Thoracic Surgeons; THV, transcatheter heart valve.
PPM (EOAi of 0.65 cm²/m² < and ≤0.85 cm²/m²) and 2 (2.6%) patients with severe PPM (which was defined as an EO Ai of ≤0.65 cm²/m²). The baseline characteristics of the study patients and the procedural characteristics of TAVI are summarized in Table 1 and Supplementary Table 1. The mean age of the study patients was 82 ± 5 years, and 50.6% of the patients were men. The mean Society of Thoracic Surgeons score was 5%, which indicates an intermediate surgical risk. Balloon-expandable THVs of 23 or 26 mm size were used in most patients. Patients with PPM were younger than patients without PPM, and no significant differences were found in sex between the PPM and non-PPM groups. Although the preoperative functional status in terms of the New York Heart Association (NYHA) functional class was similar between the groups, the post-procedure NYHA functional class tended to be higher in patients with PPM than in those without PPM; however, the

### TABLE 2 | Preoperative echocardiography characteristics.

|                     | All (n = 77) | PPM (n = 17) | Non-PPM (n = 60) | P-value (PPM vs. non-PPM) |
|---------------------|-------------|-------------|-----------------|--------------------------|
| LVEDV, ml           | 85 ± 33     | 78 ± 21     | 87 ± 26         | 0.349                    |
| LVESV, ml           | 32 ± 23     | 26 ± 11     | 34 ± 25         | 0.263                    |
| LVF, %              | 65.4 ± 10.1 | 66.9 ± 6.6  | 64.9 ± 10.9     | 0.465                    |
| SVi, ml/m²          | 42.0 ± 11.7 | 41.0 ± 8.3  | 42.3 ± 12.5     | 0.687                    |
| LVMi, g/m²          | 108 ± 30    | 109 ± 28    | 108 ± 31        | 0.883                    |
| E/A                 | 0.87 ± 0.90  | 0.87 ± 0.59  | 0.87 ± 0.98     | 0.977                    |
| E/e’                | 16.8 ± 7.2  | 16.7 ± 7.7  | 16.6 ± 7.1      | 0.961                    |
| SPAP, mmHg          | 32.1 ± 9.6  | 33.0 ± 10.1 | 31.8 ± 9.5      | 0.645                    |
| Peak velocity, m/s  | 4.3 ± 1.1   | 4.8 ± 1.4   | 4.1 ± 1.0       | 0.090                    |
| Mean PG, mmHg       | 44.9 ± 23.9 | 56.1 ± 32.3 | 41.7 ± 20.1     | 0.097                    |
| AVA, cm²/m²         | 0.64 ± 0.19 | 0.57 ± 0.16 | 0.66 ± 0.19     | 0.087                    |
| AVAi, cm²/m²        | 0.42 ± 0.12 | 0.38 ± 0.10 | 0.44 ± 0.12     | 0.064                    |

Data presented as mean ± standard deviation or n (%). LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; SVi, stroke volume index; CO, cardiac output; LVMi, left ventricular mass index; SPAP, systolic pulmonary artery pressure; Mean PG, mean transvalvular pressure gradient; AVA, aortic valve area; AVAi, aortic valve area index. The other abbreviations are shown in Table 1.

### TABLE 3 | Resting echocardiography data.

|                     | All (n = 77) | PPM (n = 17) | Non-PPM (n = 60) | P-value (PPM vs. non-PPM) |
|---------------------|-------------|-------------|-----------------|--------------------------|
| Systolic BP, mmHg   | 139 ± 22    | 141 ± 25    | 138 ± 21        | 0.596                    |
| Diastolic BP, mmHg  | 68 ± 15     | 72 ± 14     | 68 ± 16         | 0.361                    |
| Heart rate, beats/min | 67 ± 11    | 66 ± 10     | 68 ± 10         | 0.620                    |
| LVMI, g/m²          | 84 ± 24     | 84 ± 21     | 83 ± 24         | 0.889                    |
| LVEDV, ml           | 65 ± 29     | 77 ± 20     | 88 ± 31         | 0.211                    |
| LVESV, ml           | 31 ± 19     | 25 ± 8      | 33 ± 21         | 0.099                    |
| LVF, %              | 65.4 ± 10.1 | 67.4 ± 8.1  | 63.6 ± 8.8      | 0.110                    |
| SVi, ml/m²          | 49.2 ± 12.3 | 43.2 ± 11.9 | 50.9 ± 12.0     | 0.023                    |
| CO, ml/min          | 4.9 ± 1.2   | 4.2 ± 1.0   | 5.0 ± 1.1       | 0.008                    |
| E/A                 | 0.72 ± 0.18 | 0.79 ± 0.17 | 0.79 ± 0.18     | 0.105                    |
| E/e’                | 21.8 ± 9.9  | 23.0 ± 9.3  | 21.5 ± 10.1     | 0.575                    |
| SPAP, mmHg          | 29.4 ± 7.9  | 32.5 ± 8.0  | 28.0 ± 7.7      | 0.070                    |
| TAPSE/SPAP          | 0.64 ± 0.26 | 0.57 ± 0.24 | 0.66 ± 0.26     | 0.228                    |
| Pulmonary hypertension, n (%) | 7 (9.1) | 3 (17.6) | 4 (6.7) | 0.182 |
| Peak velocity, m/s  | 2.3 ± 0.46  | 2.7 ± 0.52  | 2.2 ± 0.37      | <0.001                   |
| Mean PG, mmHg       | 11.3 ± 5.0  | 16.2 ± 6.4  | 9.9 ± 3.5       | 0.001                    |
| Zva, mmHg/ml/m²     | 3.2 ± 0.81  | 3.8 ± 0.96  | 3.0 ± 0.67      | <0.001                   |
| PVL                 | 1.3 ± 0.98  | 0.91 ± 1.0  | 1.4 ± 0.95      | 0.066                    |
| EOAI, cm²/m²        | 1.08 ± 0.31 | 0.74 ± 0.07 | 1.17 ± 0.28     | <0.001                   |

Data presented as mean ± standard deviation or n (%). BP, blood pressure; TAPSE, tricuspid annular plane systolic excursion; Mean PG, mean transvalvular pressure gradient; Zva, valvulo-arterial impedance; PVL, para-valvular leak; EOA, effective orifice area; EOAI, effective orifice area index. The other abbreviations are shown in Tables 1, 2.
difference was not statistically significant. The device size used in the PPM group was smaller than that used in the non-PPM group.

Table 2 presents the preoperative echocardiographic findings. The mean LVEF was not significantly different between patients with PPM and those without PPM. The LV end-diastolic volume and LV mass index were smaller in patients with PPM than in those without PPM. Although the peak velocity was higher in patients with PPM (4.8 ± 1.4 m/s vs. 4.1 ± 1.0 m/s, \( p = 0.030 \)), mean PG and aortic valve area index were not significantly different between the two groups.

Impact of PPM on Hemodynamics at Rest and During Exercise

The hemodynamic characteristics at rest and during exercise are summarized in Tables 3, 4 and in Figures 2, 3. The relationship between the mean PG and EOAi was curvilinear, with a correlation coefficient (\( r \)) of 0.421 (\( p < 0.001 \)) at rest and 0.440 (\( p < 0.001 \)) during exercise (Figure 2). Exercise capacity was slightly higher in patients without PPM than in those with PPM, although the difference was not statistically significant. At rest, patients with PPM demonstrated a higher peak transvalvular velocity and mean PG than patients without PPM (both \( p \leq 0.001 \)). Zva and the changes in the mean PG from rest to exercise were significantly greater in patients with PPM than in patients without PPM (Zva: 4.9 ± 1.8 mmHg/ml/m² vs. 3.6 ± 0.92 mmHg/ml/m², \( \Delta \) mean PG: 5.7 ± 3.5 mmHg vs. 2.3 ± 2.8 mmHg, both \( p \leq 0.001 \), Figures 3A,B). Although there were no significant differences in the SPAP and the prevalence of PH at rest between patients with and without PPM, patients with PPM had a higher SPAP and a higher prevalence of exercise-induced PH than patients without PPM (Figure 3C; Table 4).

The results of univariate Cox proportional hazard analyses for the prediction of exercise-induced PH are presented in Table 5. Age and preoperative aortic valve area index (AVAI) were associated with exercise-induced PH. PPM was strongly associated with exercise-induced PH. Although there was no significant association between exercise-induced PH and mean PG, Zva, E/e' and blood pressure were associated with exercise-induced PH both at rest and during exercise. The

### Table 4 | Exercise stress echocardiography data.

|                      | All (\( n = 77 \)) | PPM (\( n = 17 \)) | Non-PPM (\( n = 60 \)) | \( p \)-value (PPM vs. non-PPM) |
|----------------------|-------------------|-------------------|------------------------|---------------------------------|
| Exercise duration, min | 10.3 ± 3.6        | 9.7 ± 2.4         | 10.5 ± 3.9             | 0.274                           |
| Peak watt, Watt       | 32 ± 14           | 32 ± 10           | 32 ± 14                | 0.876                           |
| Systolic BP, mmHg     | 180 ± 30          | 187 ± 21          | 178 ± 32               | 0.153                           |
| Diastolic BP, mmHg    | 76 ± 16           | 84 ± 15           | 74 ± 16                | 0.015                           |
| Heart rate, beats/min | 104 ± 18          | 107 ± 21          | 103 ± 17               | 0.354                           |
| LVEDV, ml             | 90 ± 31           | 82 ± 23           | 96 ± 32                | 0.128                           |
| LVESV, ml             | 29 ± 20           | 21 ± 10           | 31 ± 22                | 0.094                           |
| LVEF, %               | 70.8 ± 9.1        | 74.6 ± 6.1        | 69.7 ± 9.6             | 0.048                           |
| SVi, ml/m²            | 53.7 ± 14.7       | 47.2 ± 14.0       | 55.6 ± 14.5            | 0.037                           |
| CO, ml/min            | 8.2 ± 2.5         | 7.5 ± 2.5         | 8.4 ± 2.5              | 0.216                           |
| E/A                   | 1.00 ± 0.24 (\( n = 49 \)) | 0.99 ± 0.22 (\( n = 13 \)) | 1.00 ± 0.26 (\( n = 36 \)) | 0.853                           |
| E/e'                  | 21.9 ± 7.9        | 23.2 ± 9.2        | 21.5 ± 7.6             | 0.465                           |
| SPAP, mmHg            | 51.5 ± 12.0       | 57.3 ± 13.8       | 49.7 ± 10.9            | 0.021                           |
| TAPSE/SPAP            | 0.48 ± 0.15       | 0.44 ± 0.10       | 0.49 ± 0.16            | 0.230                           |
| Exercise-induced pulmonary hypertension, n (%) | 16 (20.8) | 7 (43.8) | 9 (15.0) | 0.037 |
| Peak velocity, m/s    | 2.5 ± 0.58        | 3.0 ± 0.7         | 2.4 ± 0.5              | <0.001                          |
| Mean PG, mmHg         | 14.3 ± 7.3        | 21.9 ± 9.1        | 12.2 ± 4.9             | 0.001                           |
| \( \Delta \) Mean PG, mmHg | 3.1 ± 3.2 | 5.7 ± 3.5 | 2.3 ± 2.8 | <0.001 |
| Zva, mmHg/ml/m²       | 3.9 ± 1.2         | 4.9 ± 1.8         | 3.6 ± 0.92             | 0.010                           |
| \( \Delta \) Zva, mmHg/ml/m² | 0.69 ± 1.1 | 1.1 ± 1.7 | 0.57 ± 0.89 | 0.243 |

Data presented as mean ± standard deviation or n (%). \( \Delta \) Zva, meant the change in Zva from rest to exercise. The other abbreviations are shown in Tables 1, 2.

**Figure 2** | The relationship between the mean PG and EOAi at rest and during exercise. Inverse simple regression analysis of the mean PG and EOAi at rest (\( r = 0.421; p < 0.001 \)) and during exercise (\( r = 0.440; p < 0.001 \)). Mean PG, mean transvalvular pressure gradient; EOAi, effective orifice area index.
FIGURE 3 | The changes in the mean PG, Zva and SPAP from rest to exercise. (A) mean PG increase from rest to exercise; (B) Zva increase from rest to exercise; (C) SPAP increase from rest to exercise. The increase in the mean PG and Zva from rest to exercise was greater in patients with PPM than in those without PPM. Patients with PPM had a higher SPAP increase than patients without PPM (57.3 ± 13.8 mmHg vs. 49.7 ± 10.9 mmHg). PPM = prosthesis-patient mismatch; Mean PG, mean transvalvular pressure gradient; Zva, valvulo-arterial impedance; SPAP, systolic pulmonary artery pressure.

TABLE 5 | Univariate models of Cox regression analysis for exercise induced pulmonary hypertension.

| Univariate |  |  |
|---|---|---|
| Univariate | HR | 95% CI | p-value |
| Patient characteristics |  |  |  |
| Female sex | 1.020 | 0.375–2.769 | 0.970 |
| Age | 0.902 | 0.824–0.987 | 0.024 |
| Atrial fibrillation | 0.816 | 0.281–2.367 | 0.708 |
| Preoperative echocardiography |  |  |  |
| SVi | 0.986 | 0.943–1.031 | 0.529 |
| SPAP | 1.019 | 0.976–1.063 | 0.401 |
| E/A | 1.120 | 0.575–2.184 | 0.738 |
| E/e’ | 1.064 | 0.993–1.140 | 0.078 |
| AVAi | 0.006 | 0.000–0.909 | 0.046 |
| Mean PG | 1.010 | 0.995–1.026 | 0.199 |
| Exercise echocardiography |  |  |  |
| Rest systolic BP | 1.038 | 1.013–1.063 | 0.003 |
| Rest diastolic BP | 1.031 | 1.008–1.054 | 0.007 |
| Rest SVi | 1.002 | 0.957–1.048 | 0.942 |
| Rest CO | 0.923 | 0.554–1.537 | 0.758 |
| Rest SPAP | 1.063 | 1.019–1.110 | 0.005 |
| Rest E/A | 35.132 | 3.062–403.1 | 0.004 |
| Rest E/e’ | 1.082 | 1.019–1.148 | 0.009 |
| PPM | 3.570 | 1.304–9.778 | 0.013 |
| Rest Mean PG | 1.058 | 0.997–1.123 | 0.064 |
| Rest Zva | 2.025 | 1.108–3.701 | 0.022 |
| Peak systolic BP | 1.040 | 1.015–1.065 | 0.001 |
| Peak diastolic BP | 1.091 | 1.044–1.140 | <0.001 |
| SVi during exercise | 0.985 | 0.953–1.019 | 0.386 |
| CO during exercise | 0.994 | 0.834–1.183 | 0.943 |
| E/A during exercise | 1.112 | 0.886–1.414 | 0.935 |
| E/e’ during exercise | 1.087 | 1.019–1.159 | 0.011 |
| Mean PG during exercise | 1.039 | 0.998–1.082 | 0.066 |
| Zva during exercise | 1.728 | 1.179–2.534 | 0.005 |

HR, hazard ratio; CI, confidence interval. The other abbreviations are shown in Tables 1–3.

Prognostic Impact of PPM
During the 28 ± 10 months follow-up period, 19 patients reported the primary composite endpoint and five patients had the secondary endpoint of heart failure-related hospitalization. Kaplan-Meier survival curves (Figure 5) did not show any significant differences in both primary and secondary endpoints between patients with and without PPM (primary endpoint: log-rank \( \chi^2 = 0.210, p = 0.647 \); secondary endpoints: log-rank \( \chi^2 = 0.181, p = 0.671 \)).

DISCUSSION
The major findings of this study are as follows: (1) The EOAi at rest correlated well with the mean PG at rest and during exercise; (2) patients with PPM showed a disproportionate increase in the transvalvular PG, LV afterload, and SPAP during exercise compared with patients without PPM; (3) the prevalence of exercise-induced PH after TAVI was higher in the PPM group than in the non-PPM group, and the improvement of symptoms tended to be poor in the PPM
group; and (4) PPM was not associated with all-cause mortality or heart failure-related hospitalization during 2 years in this cohort.

Hemodynamic Changes During Exercise

Some previously published reports (15–17) have addressed the hemodynamic characteristics of various surgical aortic prosthetic valves during exercise. To the best of our knowledge, this is the first study to assess the hemodynamic characteristics of THVs during exercise using ESE. Pibarot (15, 16) reported that PPM is associated with a marked increase in the mean PG and the prevalence of PH, whereas a normal functional prosthetic valve shows a minimal increase in the mean PG. These findings regarding surgical prosthesis were consistent with the major findings of our study that included AS patients after TAVI. O’Sullivan et al. (18) demonstrated that postcapillary PH (left-sided PH) is the most common form of PH among patients with severe symptomatic AS undergoing TAVI. In postcapillary PH, the increased SPAP is mainly thought to be due to the passive backward transmission of an increased LV filling pressure (19, 20). Although the SPAP usually correlates with the CO, our study also found that patients with PPM had a higher SPAP during exercise despite a lower CO than patients without PPM. These findings suggest that the LV afterload during exercise was higher in the PPM group than in the non-PPM group and that the impaired LV diastolic function, increased LV filling and left atrial
pressure are causes of disproportionate increase in pulmonary artery pressure. However, no statistically significant difference was noted in the diastolic function parameters, including the E/A ratio in our study. Despite of the fact that the mitral variables the mitral variables of the E/A ratio are the main parameters for evaluating diastolic function, many studies reported there is a weak correlation between the echocardiographic indices of the LV diastolic function and the LV filling pressure in patients with LV hypertrophy (21–23). In addition, the presence of mitral annular calcification reportedly underestimates the e' value (24, 25) in this study, mitral annular calcification was observed in ~30% of the patients, which is considered to be one of the reasons for the lack of difference in the E/e' ratio.

Clinical Impact of PPM

Many studies have documented the negative clinical impact of PPM after surgical aortic valve replacement (SAVR) and TAVI, focusing on clinical outcomes such as survival (3–6, 8, 9), heart failure worsening (8), LV mass regression (5, 6), and valve durability (7). Bleiziffer S (17) reported that the presence of PPM significantly influences the percentage of predicted exercise capacity and impairs the quality of life in patients. Although no statistically significant difference was found in our study in terms of adverse events, the post-procedure NYHA functional class was higher in patients with PPM than in patients without PPM. The transvalvular PG and SPAP were higher in patients with PPM than in patients without PPM, and the prevalence of exercise-induced PH was higher in patients with PPM (Figure 3), which resulted in a higher NYHA functional class. We speculated that an increased hemodynamic burden due to higher gradients in patients with PPM could explain this phenomenon. Another possible explanation is that PPM may limit the increase in the CO (Figure 4). This may, in turn, limit the capacity of cardiac function to match the increasing metabolic demand during exercise.

In our study, there were no differences in the hard endpoints between the PPM and non-PPM groups (Figure 5). The reasons for this possibly include the short follow-up period, elderly patients, and inclusion of exercisable patients only. It is important to estimate the postoperative EOA and predict PPM from preoperative cardiac imaging. In this study, prosthetic valve EOA tended to increase with preoperative annulus area, and each value was similar to the previously reported valve area in the CoreLab analysis (26) (Supplementary Table 1). It is desirable to predict prosthetic valve size and determine the predicted EOA and PPM from preoperative imaging data and select treatment strategy accordingly.

A previous study with a similar follow-up in AS patients after TAVI reported that only severe PPM was associated with prognosis (6, 8). Moreover, Schofer et al. (9) reported that in patients with low LVEF (<40%), severe PPM was associated with increased risk of mortality. In our study, severe PPM was noted in only two patients, and no patient had low LVEF or severe PPM.

LIMITATIONS

This study was performed with a relatively small number of patients. Nonetheless, our findings are new, and important implications were made regarding the behavior of the transcatheter aortic valve during exercise. In this study, only balloon-expandable THV was examined, and the study of hemodynamics during exercise in patients with Self-expandable THVs and comparison with prosthetic valve types is warranted. It is unknown whether ESE performed at 3–6 months after TAVI is valid in terms of the time period for evaluating the impact of PPM on hemodynamics. Most patients in our study were elderly; therefore, it was difficult to perform ESE in such patients after long periods. Some patients, including young and low-risk patients, in previous studies (17) underwent ESE from 5 to 12 months after SAVR. Further studies are necessary to investigate PPM in post-TAVI patients after longer periods.

CONCLUSION

AS patients with PPM after TAVI showed a disproportionate increase in the transvalvular gradient and SPAP during exercise. In addition, PPM was associated with exercise-induced PH.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Institutional Review Board of the St. Marianna University School of Medicine. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

MI contributed to conception and design of the study. HK performed the statistical analysis. HK and MI wrote the manuscript. YA helped revise the manuscript. All authors organized the database and read and approved the submitted version.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2021.799285/full#supplementary-material
REFERENCES

1. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. (2019) 380:1695–705. doi: 10.1056/NEJMoa1814052

2. Rahimtoola SH. The problem of valve prosthesis-patient mismatch. Circulation. (1978) 58:20–4. doi: 10.1161/01.CIR.58.1.20

3. Blais C, Dumesnil JG, Ballot R, Simard S, Doyle D, Pibarot P. Impact of valve prosthesis-patient mismatch on short-term mortality after aortic valve replacement. Circulation. (2003) 108:983–8. doi: 10.1161/01.CIR.0000085167.67105.32

4. Head SJ, Mokhles MM, Osnabrugge RL, Pibarot P, Mack MJ, Takkenberg JJ, et al. The impact of prosthesis–patient mismatch on long-term survival after aortic valve replacement: a systematic review and meta-analysis of 34 observational studies comprising 27 186 patients with 133 141 patient-years. European heart journal. (2012) 33:1518–29. doi: 10.1093/eurheartj/eho003

5. Dayan V, Vignolo G, Soca G, Paganini JJ, Brusich D, Pibarot P. Predictors and outcomes of prosthesis-patient mismatch after aortic valve replacement. JACC Cardiovasc Imaging. (2016) 9:924–33. doi: 10.1016/j.jcmg.2015.10.026

6. Pibarot P, Weissman NJ, Stewart WJ, Hahn RT, Lindman BR, McAndrew T, et al. Incidence and sequelae of prosthesis-patient mismatch in transcatheter versus surgical valve replacement in high-risk patients with severe aortic stenosis: a PARTNER trial cohort-analysis. J Am Coll Cardiol. (2014) 63:1233–34. doi: 10.1016/j.jacc.2014.06.1195

7. Flameng W, Herzegods MC, Vercalsteren M, Herijgers P, Bogaerts K, Meuris B. Prosthesis-patient mismatch predicts structural valve degeneration by bioprothetic heart valves. Circulation. (2010) 121:2123–9. doi: 10.1161/CIRCULATIONAHA.109.901272

8. Herrmann HC, Daneshvar SA, Fonarow GC, Stebbins A, Vemulapalli S, Desai M, et al. Prosthesis-patient mismatch after transcatheter aortic valve implantation: prevalence and prognostic impact with respect to baseline left ventricular function. EuroIntervention. (2019) 14:1648–55. doi: 10.4244/EIJ-D-18-00827

9. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. (2015) 16:233–70. doi: 10.1093/ehjci/jev014

10. Lancellotti P, Pibarot P, Chambers J, Edvardsen T, Delgado V, Dulgheru R, et al.Recommendations for the imaging assessment of prosthetic heart valves: a report from the European Association of Cardiovascular Imaging endorsed by the Chinese Society of Echocardiography, the Inter-American Society of Echocardiography, and the Brazilian Department of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. (2016) 17:589–90. doi: 10.1093/ehjci/jew025

11. Baumgartner H, Hung J, Bermejo J, Chambers JB, Edvardsen T, Goldstein S, et al. Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr. (2017) 30:372–92. doi: 10.1016/j.echo.2017.02.009

12. Pibarot P, Hahn RT, Weissman NJ, Monaghan MJ. Assessment of paravalvular regurgitation following TAVR: a proposal of unifying grading scheme. JACC Cardiovasc Imaging. (2015) 8:340–60. doi: 10.1016/j.jcmg.2015.01.008

13. Achenbach S, Delgado V, Hausleiter J, Schoenhagen P, Min JK, Leipsic JA. SCCT expert consensus document on computed tomography imaging before transcatheter aortic valve implantation (TAVI)/transcatheter aortic valve replacement (TAVR). J Cardiovasc Comput Tomogr. (2012) 6:366–80. doi: 10.1016/j.jcct.2012.11.002

14. Pibarot P, Dumesnil JG, Jobin J, Cartier P, Honos G, Durand LG. Hemodynamic and physical performance during maximal exercise in patients with an aortic bioprosthetic valve: comparison of stentless versus stented bioprostheses. J Am Coll Cardiol. (1999) 34:1609–17. doi: 10.1016/S0735-1097(99)00360-5

15. Pibarot P, Dumesnil JG, Jobin J, Lemieux M, Honos G, Durand LG. Usefulness of the indexed effective orifice area at rest in predicting an increase in gradient during maximum exercise in patients with a bioprosthesis in the aortic valve position. Am J Cardiol. (1999) 83:542–6. doi: 10.1016/S0002-9149(99)00910-2

16. Bleiziffer S, Eichinger WB, Hettich I, Ruzicka D, Wottke M, Bauerhanssmit R, et al. Impact of patient-prosthesis mismatch on exercise capacity in patients after bioprosthetic aortic valve replacement. Heart. (2008) 94:657–41. doi: 10.1136/hrt.2007.116673

17. O’Sullivan CJ, Wenaweser P, Ceylan O, Rat-Wirtzler J, Stortecky S, Heg D, et al. Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheter aortic valve implantation: insights from the new proposed pulmonary hypertension classification. Circ Cardiovasc Interventions. (2015) 8:e002358. doi: 10.1161/CIRCINTERVENTIONS.114.002358

18. Guazzi M, Borlaug BA. Pulmonary hypertension due to left heart disease. Circulation. (2012) 126:975–90. doi: 10.1161/CIRCULATIONAHA.111.085761

19. Bossone E, D’Andrea A, D’Alto M, Citro R, Argiento P, Bella F, et al. Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis. J Am Soc Echocardiogr. (2013) 26:1–14. doi: 10.1016/j.echo.2012.10.009

20. Nishimura RA, Appleton CP, Redfield MM, Istrup DM, Holmes DR, Tajik AJ. Noninvasive Doppler echocardiographic evaluation of left ventricular filling pressures in patients with cardiomyopathies: a simultaneous Doppler echocardiographic and cardiac catheterization study. J Am Coll Cardiol. (1996) 28:1226–33. doi: 10.1016/S0735-1097(96)00315-4

21. Nagueh SF, Lakkis NM, Middleton KL, Spencer III WH, Zoghbi WA, Quinones MA. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation. (1999) 99:254–61. doi: 10.1161/01.CIR.99.2.254

22. Geske JB, Sorajja P, Nishimura RA, Ommen SR. Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy: correlation with direct left atrial pressure measurement at cardiac catheterization. Circulation. (2007) 116:2702–8. doi: 10.1161/CIRCULATIONAHA.107.698985

23. Soëkki T, Fukuda N, Shinohara H, Sakabe K, Onose Y, Sawada Y, et al. Mitral inflow and mitral annular motion velocities in patients with mitral annular calcification: evaluation by pulsed Doppler echocardiography and pulsed Doppler tissue imaging. Eur J Echocardiogr. (2002) 3:312–31. doi: 10.1053/euje.2001.0137

24. Abubia MM, Chebrolu LH, Schutt RC, Nagueh SF, Zoghbi WA, Doppler echocardiography for the estimation of LV filling pressure in patients with mitral annular calcification. JACC Cardiovasc Imaging. (2017) 10:1411–20. doi: 10.1016/j.jcmg.2016.10.017

25. Hahn RT, Leipsic J, Douglas PS, Jaber WA, Weissman NJ, Pibarot P, Vemulapalli S. Comprehensive echocardiographic assessment of normal transcatheter valve function. JACC Cardiovasc Imaging. (2019) 12:25–34. doi: 10.1016/j.jcmg.2018.04.010

Conflict of Interest: MI is a screening proctor for Edwards Lifesciences.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Kameshima, Izumo, Suzuki, Ohara, Satô, Watanabe, Okuyama, Kamijima, Takai, Kou, Tanabe, Harada and Akashi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.